ATE498392T1 - Ophthalmische emulsionen mit einem immunsuppressiven mittel - Google Patents

Ophthalmische emulsionen mit einem immunsuppressiven mittel

Info

Publication number
ATE498392T1
ATE498392T1 AT08102553T AT08102553T ATE498392T1 AT E498392 T1 ATE498392 T1 AT E498392T1 AT 08102553 T AT08102553 T AT 08102553T AT 08102553 T AT08102553 T AT 08102553T AT E498392 T1 ATE498392 T1 AT E498392T1
Authority
AT
Austria
Prior art keywords
emulsions containing
ophthalmic emulsions
immunosupressive agent
agent
immunosupressive
Prior art date
Application number
AT08102553T
Other languages
English (en)
Inventor
Betty Philips
Severine Bague
Laura Rabinovich-Guilatt
Gregory Lambert
Original Assignee
Novagali Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34931510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE498392(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novagali Pharma Sa filed Critical Novagali Pharma Sa
Application granted granted Critical
Publication of ATE498392T1 publication Critical patent/ATE498392T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Colloid Chemistry (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
AT08102553T 2004-11-09 2005-10-10 Ophthalmische emulsionen mit einem immunsuppressiven mittel ATE498392T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04292645A EP1655021B1 (de) 2004-11-09 2004-11-09 Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential
US10/991,346 US8298568B2 (en) 2004-11-09 2004-11-18 Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential

Publications (1)

Publication Number Publication Date
ATE498392T1 true ATE498392T1 (de) 2011-03-15

Family

ID=34931510

Family Applications (5)

Application Number Title Priority Date Filing Date
AT04292645T ATE412400T1 (de) 2004-11-09 2004-11-09 Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
AT05800012T ATE415942T1 (de) 2004-11-09 2005-10-10 Prostaglandine enthaltende ophthalmische emulsionen
AT08102553T ATE498392T1 (de) 2004-11-09 2005-10-10 Ophthalmische emulsionen mit einem immunsuppressiven mittel
AT05795930T ATE418964T1 (de) 2004-11-09 2005-10-10 Ophthalmische öl-in-wasser-emulsion mit stabilem positivem zeta-potential
AT05802097T ATE412401T1 (de) 2004-11-09 2005-10-10 Ophthalmische emulsion mit einem immunosuppressiven mittel

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT04292645T ATE412400T1 (de) 2004-11-09 2004-11-09 Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
AT05800012T ATE415942T1 (de) 2004-11-09 2005-10-10 Prostaglandine enthaltende ophthalmische emulsionen

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT05795930T ATE418964T1 (de) 2004-11-09 2005-10-10 Ophthalmische öl-in-wasser-emulsion mit stabilem positivem zeta-potential
AT05802097T ATE412401T1 (de) 2004-11-09 2005-10-10 Ophthalmische emulsion mit einem immunosuppressiven mittel

Country Status (13)

Country Link
US (5) US8298568B2 (de)
EP (1) EP1655021B1 (de)
JP (3) JP5587936B2 (de)
CN (3) CN103356481B (de)
AT (5) ATE412400T1 (de)
DE (5) DE602004017477D1 (de)
DK (1) DK1809237T3 (de)
ES (4) ES2314354T3 (de)
IL (3) IL181446A (de)
MX (2) MX2007003045A (de)
NZ (1) NZ554929A (de)
PT (2) PT1809237E (de)
ZA (1) ZA200703751B (de)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US8232320B2 (en) 1999-04-28 2012-07-31 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
US7655252B2 (en) 1999-04-28 2010-02-02 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
ES2314354T3 (es) * 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
CA2604392A1 (en) * 2005-04-11 2006-10-19 Nanobio Corporation Quaternary ammonium halides for treatment of infectious conditions
US7297679B2 (en) * 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
EP1951200A2 (de) * 2005-08-09 2008-08-06 Nanobio Corporation Eine nanoemulsion enthaltende zusammensetzungen mit entzündungshemmender wirkung
US7797337B2 (en) * 2005-09-29 2010-09-14 Scenera Technologies, Llc Methods, systems, and computer program products for automatically associating data with a resource as metadata based on a characteristic of the resource
CA2645080A1 (en) * 2006-03-07 2007-09-13 Novavax,Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
US10137083B2 (en) * 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
US11311477B2 (en) 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
WO2007111806A2 (en) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
US20080026013A1 (en) * 2006-07-28 2008-01-31 Laura Rabinovich-Guilatt Compositions containing quaternary ammonium compounds
ES2428868T3 (es) * 2006-07-28 2013-11-12 Novagali Pharma S.A. Composiciones que contienen compuestos de amonio cuaternario
WO2008035246A2 (en) 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
US9132071B2 (en) * 2006-07-28 2015-09-15 Santen Sas Compositions containing quaternary ammonium compounds
AU2014201978B2 (en) * 2006-07-28 2016-03-10 Santen Sas Compositions containing quaternary ammonium compounds
EP2444829A1 (de) 2006-09-14 2012-04-25 Carl Zeiss SMT GmbH Optische Elementeinheit und Verfahren zum Stützen eines optischen Elements
EP1938801A1 (de) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
EP1985298A1 (de) 2007-04-24 2008-10-29 Azad Pharma AG Prostaglandinhaltige Öl-in-Wasser-Emulsionen für das Auge
US8747872B2 (en) 2007-05-02 2014-06-10 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US8512687B2 (en) * 2007-07-09 2013-08-20 Novagali Pharma Sa Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
US20090018057A1 (en) * 2007-07-09 2009-01-15 Gregory Lambert OIL IN WATER EMULSION COMPRISING NSAIDs AND QUATERNARY AMMONIUM HALIDES
EP2197449A4 (de) * 2007-10-16 2013-10-09 Sun Pharma Advanced Res Co Ltd Neuartige ophthalmische zusammensetzungen
US7834172B2 (en) * 2007-11-14 2010-11-16 Novagali Pharma Sa Composition comprising at least one nucleosidic moiety as a therapeutic agent, and CKC
WO2009063081A2 (en) * 2007-11-14 2009-05-22 Novagali Pharma Sa Composition comprising at least one nucleosidic moiety as a therapeutic agent, and ckc.
EP2077105A1 (de) * 2008-01-02 2009-07-08 Novagali Pharma SA Ophthalmische mizellare Zusammensetzung mit erhöhter Stabilität
EP2077104A1 (de) * 2008-01-02 2009-07-08 Novagali Pharma SA Mizellare Zusammensetzungen mit ophtalmischen Anwendungen
EP2127638A1 (de) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom
BRPI0918244A2 (pt) * 2008-09-04 2015-12-15 Santen Pharmaceutical Co Ltd E Asahi Glass Company Ltd agente promotor do crescimento de pelos, e método para prevenir ou tratar uma doença associada com os cabelos.
BRPI0918806B1 (pt) * 2008-09-05 2019-02-05 Ceva Sante Animale Sa Composição de vacina compreendendo quitosana e antígeno do vírus de doença de newcastle (nvd) adaptada à administração ocular em ave, uso de quitosana e de nvd paraaumentar resposta imune em ave, bem como kit de vacinação de aves
WO2010057197A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
CN102395401B (zh) 2009-02-12 2015-08-19 因赛普特有限责任公司 经由水凝胶塞的药物递送
EP2228058A1 (de) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionische Öl-in-Wasser-Emulsion mit Prostaglandinen und Verwendungen dafür
EP2228057A1 (de) * 2009-03-04 2010-09-15 Novagali Pharma S.A. Kationische Öl-in-Wasser-Emulsionen mit Prostaglandinen und Verwendungen dafür
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US20130011354A1 (en) * 2009-11-09 2013-01-10 Allergan, Inc. Compositions For Enhancing Hair Growth
EP2389939A1 (de) 2010-05-28 2011-11-30 Novagali Pharma S.A. Verwendung von Prostaglandinen F2alpha und Analoga zur Heilung von Horn- und Bindehautläsionen
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
US9087145B2 (en) * 2010-07-15 2015-07-21 Eyenovia, Inc. Ophthalmic drug delivery
SG187770A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
EP3378480A1 (de) 2011-01-19 2018-09-26 Topokine Therapeutics, Inc. Verfahren und zusammensetzungen zur behandlung des stoffwechselsyndroms
PL2667877T3 (pl) 2011-01-26 2018-09-28 Allergan, Inc. Kompozycja androgenu do leczenia stanu okulistycznego
WO2013011511A1 (en) 2011-07-18 2013-01-24 Mor Research Applications Ltd. A device for adjusting the intraocular pressure
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
AU2012339701B8 (en) 2011-11-15 2017-11-16 Allergan, Inc. Autoclavable suspensions of cyclosporin A Form 2
CN104080442B (zh) 2011-11-15 2018-01-05 阿勒根公司 环孢菌素a形式2的悬浮液
CN109200013A (zh) 2011-12-05 2019-01-15 因赛普特有限责任公司 医用有机凝胶方法和组合物
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
JP5992031B2 (ja) * 2012-02-24 2016-09-14 ファインバイオメディカル有限会社 潤滑性調整液
ES2948387T3 (es) 2012-08-24 2023-09-11 Sun Pharmaceutical Ind Ltd Formulación oftálmica de ácidos grasos polioxílicos o lípidos polioxílicos y tratamiento de afecciones oculares
SG10201701773UA (en) * 2012-09-06 2017-04-27 Univ Nanyang Tech Hyaluronic Acid-Based Drug Delivery Systems
CN104936595A (zh) 2012-11-21 2015-09-23 托普凯恩制药公司 局部增加体脂肪的方法和组合物
DK2948134T3 (da) 2013-01-24 2020-06-02 Palvella Therapeutics Inc Sammensætninger til transdermal indgivelse af mtor-inhibitorer
CA2939952C (en) 2013-03-05 2022-03-22 Morgan V. Fedorchak Thermoresponsive hydrogel containing polymer microparticles for noninvasive ocular drug delivery
US20160022648A1 (en) * 2013-03-13 2016-01-28 Santen Pharmaceutical Co., Ltd. Therapeutic agent for meibomian gland dysfunction
US20140275261A1 (en) * 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
RU2513597C1 (ru) * 2013-04-17 2014-04-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) Способ лечения воспалительных состояний переднего отрезка глаза
NO2753788T3 (de) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
EP3013790A1 (de) 2013-06-27 2016-05-04 Mylan Laboratories Ltd. Verfahren zur herstellung von nepafenac
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
EP3104840B8 (de) 2014-02-11 2019-07-10 Latitude Pharmaceuticals Inc. Parenterale zusammensetzungen von celecoxib
CN106456541A (zh) * 2014-02-14 2017-02-22 黄敬珺 纳米乳传递系统组合物
US20170087096A1 (en) * 2014-06-13 2017-03-30 Sanofi Nanocapsular formulation of active pharmaceutical ingredients
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
JP2017538728A (ja) * 2014-12-19 2017-12-28 ケミン、インダストリーズ、インコーポレーテッドＫｅｍｉｎ Ｉｎｄｕｓｔｒｉｅｓ， Ｉｎｃ． イオントフォレシスを用いた生物活性分子の眼内送達
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
WO2016127022A1 (en) * 2015-02-06 2016-08-11 Foreman James Michael Preparation of an oil-in-water emulsion for polymer stabilized pharmaceutical formulations
CN106176600A (zh) * 2015-05-07 2016-12-07 上海现代药物制剂工程研究中心有限公司 一种前列地尔冻干微乳剂、原料组合物及其制备方法
WO2016182926A1 (en) * 2015-05-08 2016-11-17 Affinsci Inc. Preparation of nanoemulsions
DK3373976T3 (da) 2015-11-10 2024-04-02 Sun Pharmaceutical Ind Ltd Topiske formuleringer og anvendelser deraf
PT3423076T (pt) 2016-02-29 2024-07-01 Sun Pharmaceutical Ind Ltd Formulações tópicas contendo ciclosporina e respetivas utilizações
JP6906899B2 (ja) * 2016-03-30 2021-07-21 小林製薬株式会社 乳化組成物
WO2017192773A1 (en) 2016-05-03 2017-11-09 Pneuma Respiratory, Inc. Methods for treatment of pulmonary lung diseases with improved therapeutic efficacy and improved dose efficiency
EP4591994A3 (de) 2016-05-03 2025-10-01 Pneuma Respiratory, Inc. Tröpfchenabgabevorrichtung zur erzeugung und abgabe von tröpfchen an das lungensystem
AU2017260444B2 (en) 2016-05-03 2019-05-09 Pneuma Respiratory, Inc. Droplet delivery device for delivery of fluids to the pulmonary system and methods of use
WO2017192774A1 (en) 2016-05-03 2017-11-09 Pneuma Respiratory, Inc. Methods for the systemic delivery of therapeutic agents to the pulmonary system using a droplet delivery device
US11285285B2 (en) 2016-05-03 2022-03-29 Pneuma Respiratory, Inc. Systems and methods comprising a droplet delivery device and a breathing assist device for therapeutic treatment
US11395853B2 (en) 2016-06-23 2022-07-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions
RS58292B1 (sr) * 2016-07-07 2019-03-29 Salvat Lab Sa Oftalmološka kompozicija sa ricinusovim uljem i srednjim lancem triglicerida
CN106782348A (zh) * 2017-01-04 2017-05-31 深圳市华星光电技术有限公司 一种led背光驱动电路及液晶显示器
CN110520097B (zh) 2017-01-06 2023-10-27 帕尔维拉治疗股份有限公司 Mtor抑制剂的无水组合物及其使用方法
WO2018213834A1 (en) 2017-05-19 2018-11-22 Pneuma Respiratory, Inc. Dry powder delivery device and methods of use
EP3630042A4 (de) * 2017-05-30 2021-06-23 Eximore Ltd. Zusammensetzungen und verfahren zur behandlung von trockenem auge mittels freisetzung von antibiotischem macrolid
KR102643190B1 (ko) 2017-06-10 2024-03-04 아이노비아 인코포레이티드 유체를 취급하기 위한, 그리고 눈에 유체를 전달하기 위한 디바이스들
CN118203735A (zh) 2017-10-04 2024-06-18 精呼吸股份有限公司 电子呼吸致动式直线型液滴输送装置及其使用方法
EP4696353A2 (de) 2017-10-17 2026-02-18 Pneuma Respiratory, Inc. Vorrichtung zur nasalen arzneimittelverabreichung
WO2019089573A1 (en) 2017-10-30 2019-05-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Treatment of ocular conditions utilizing a histone/protein deacetylase inhibitor
EP3706843B1 (de) 2017-11-08 2024-06-26 Pneuma Respiratory, Inc. Elektronische atembetätigte inline-tröpfchenabgabevorrichtung mit kleinvolumiger ampulle
AU2019226051B2 (en) * 2018-02-26 2024-05-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Drug delivery systems
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
CN109010268B (zh) * 2018-09-28 2020-07-10 湖北远大天天明制药有限公司 一种提高氯霉素稳定性的眼用组合物及其制备方法
SG11202106144VA (en) 2018-12-11 2021-07-29 Disruption Labs Inc Compositions for the delivery of therapeutic agents and methods of use and making thereof
CN110237233B (zh) * 2019-07-30 2021-01-15 沈阳兴齐眼药股份有限公司 一种含有环孢素的眼用药物组合物、其制备方法及用途
MX2022006803A (es) * 2019-12-04 2022-09-19 Restore Vision Llc Formulaciones oftalmicas para el tratamiento de la presbicia.
CN115038414A (zh) 2019-12-11 2022-09-09 艾诺维亚股份有限公司 用于向眼睛输送流体的系统和装置及使用方法
US20230210771A1 (en) * 2020-06-10 2023-07-06 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
ES3040366T3 (en) 2021-06-22 2025-10-30 Pneuma Respiratory Inc Droplet delivery device with push ejection
WO2023004813A1 (zh) 2021-07-30 2023-02-02 京东方科技集团股份有限公司 像素电路、驱动方法和显示装置
CN113577024B (zh) * 2021-08-20 2023-05-05 山西利普达医药科技有限公司 一种眼用组合物及其制备方法和应用
CN116407499B (zh) * 2021-12-29 2024-10-25 辅必成（上海）医药科技有限公司 一种他克莫司眼用乳剂及其制备方法
US12161795B2 (en) 2022-07-18 2024-12-10 Pneuma Respiratory, Inc. Small step size and high resolution aerosol generation system and method
WO2024208433A1 (en) 2023-04-06 2024-10-10 Biofrontera Bioscience Gmbh Nanoemulsion without propylene glycol
WO2024208434A1 (en) 2023-04-06 2024-10-10 Biofrontera Bioscience Gmbh Pressurized nanoemulsion
AU2024315262A1 (en) * 2023-08-03 2026-02-26 Arcum Vision Inc. Enhanced formulation of polymyxin b/ trimethoprim and rifampin and methods for ophthalmic uses
CN120960148A (zh) * 2025-09-15 2025-11-18 安徽辰旭视光科技有限公司 一种用于治疗免疫性干眼症的眼用纳米乳制剂及其制备方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
JPH0818989B2 (ja) 1984-01-12 1996-02-28 株式会社ミドリ十字 脂肪乳剤中のプロスタグランジンの安定化方法
US4839342A (en) * 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
JP2602964B2 (ja) 1989-10-16 1997-04-23 裕 水島 プロスタグランジン類縁体およびその脂肪乳剤
IL101241A (en) * 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
IL103907A0 (en) * 1992-11-27 1993-04-04 Pharmos Corp Ophthalmic compositions
AU680813B2 (en) * 1992-08-28 1997-08-14 Pharmos Corporation Submicron emulsions as ocular drug delivery vehicles
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
JP3551977B2 (ja) * 1993-04-08 2004-08-11 ライオン株式会社 安定なビタミンａ類及びビタミンｅ類可溶化点眼剤
EP0631770B1 (de) * 1993-06-25 1998-07-22 Alcon Cusi, S.A. Neue Verwendung von polymeren Membranen zum Ausgeben von pharmazeutischen Lösungen, die quarternäre, als Konserviermittel dienende Ammoniumverbindungen enthalten und entsprechender Dosierbehälter
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JP2936209B2 (ja) * 1994-06-01 1999-08-23 ユーハン コーポレーション サイクロスポリン含有組成物およびその製造方法
ES2094688B1 (es) * 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6011062A (en) 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5767153A (en) * 1995-06-07 1998-06-16 Insite Vision Incorporated Sustained release emulsions
DE69807281T2 (de) 1997-05-14 2003-04-17 Mitsubishi Chemical Corp., Tokio/Tokyo Difluprednat enthaltende Zusammensetzungen
JP3410364B2 (ja) * 1997-05-14 2003-05-26 千寿製薬株式会社 ジフルプレドナート含有組成物
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
US6225348B1 (en) * 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
AU2183900A (en) * 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
US20020136771A1 (en) * 1998-12-31 2002-09-26 Amitee Cosmetics, Inc. Stabilized ascorbic acid composition
FR2823441B1 (fr) * 2001-04-12 2004-09-10 Thea Lab Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie et son procede de preparation
WO2002085248A2 (en) * 2001-04-23 2002-10-31 Board Of Regents The University Of Texas System Prostanoids augment ocular drug penetration
EP2545937A1 (de) * 2001-06-05 2013-01-16 The Regents Of The University Of Michigan Nanoemulsionsimpfstoffe
US6872705B2 (en) * 2001-07-13 2005-03-29 Allergan, Inc. Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions
US6656460B2 (en) * 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
AU2002214233A1 (en) * 2001-11-01 2003-07-09 Novagali Pharma Sa Method and composition for dry eye treatment
KR100446960B1 (ko) 2001-12-04 2004-09-01 김종국 프로스타글란딘 ｅ1을 포함하는 온도감응성 에멀젼 외용제조성물
US20030165545A1 (en) * 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
US20050124699A1 (en) * 2002-07-02 2005-06-09 Wakamoto Pharmaceutical Co., Ltd. Drugs for treating or preventing disorders of corneal and/or conjunctival epithelial cells
US20050228048A1 (en) 2002-08-23 2005-10-13 Santen Pharmaceutical Co., Ltd. Stable eye drops containing latanoprost as the active ingredient
EP1547599B1 (de) 2002-09-09 2017-11-01 Santen Pharmaceutical Co., Ltd. Transparente augentropfen mit latanoprost
US20040115234A1 (en) * 2002-09-24 2004-06-17 Gewirtz Joan T. Cosmetic composition
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
JP4361294B2 (ja) * 2003-02-25 2009-11-11 ロート製薬株式会社 ケトチフェン含有組成物
JP4694773B2 (ja) * 2003-06-06 2011-06-08 ロート製薬株式会社 粘膜適用液状組成物
US20050059583A1 (en) * 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
JP5382972B2 (ja) * 2003-12-26 2014-01-08 ロート製薬株式会社 粘度低下が防止された組成物
US20050175651A1 (en) * 2004-01-09 2005-08-11 L'oreal Aqueous dispersion of nanocapsules with an oily core
DE602004022523D1 (de) 2004-07-02 2009-09-24 Novagali Pharma Sa Verwendung von Emulsionen zur intra- und periocularen Injection
JP4999304B2 (ja) * 2004-09-27 2012-08-15 ロート製薬株式会社 ヒアルロン酸又はその塩を含有する粘膜適用組成物
EP1827373B1 (de) * 2004-11-09 2008-12-03 Novagali Pharma SA Prostaglandine enthaltende ophthalmische emulsionen
ES2314354T3 (es) * 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
US20090169629A1 (en) * 2008-01-02 2009-07-02 Novagali Pharma Sa Micellar compositions with ophthalmic applications
US20090170944A1 (en) * 2008-01-02 2009-07-02 Novagali Pharma Sa Ophthalmic micellar compositions with enhanced stability
US20090298956A1 (en) * 2008-05-28 2009-12-03 Chowhan Masood A Self-preserved emulsions
EP2228057A1 (de) * 2009-03-04 2010-09-15 Novagali Pharma S.A. Kationische Öl-in-Wasser-Emulsionen mit Prostaglandinen und Verwendungen dafür
EP2228058A1 (de) * 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionische Öl-in-Wasser-Emulsion mit Prostaglandinen und Verwendungen dafür
EP2389939A1 (de) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Verwendung von Prostaglandinen F2alpha und Analoga zur Heilung von Horn- und Bindehautläsionen

Also Published As

Publication number Publication date
US20080268020A1 (en) 2008-10-30
HK1112411A1 (en) 2008-09-05
EP1655021B1 (de) 2008-10-29
JP5587936B2 (ja) 2014-09-10
DE602005012136D1 (de) 2009-02-12
JP2012149102A (ja) 2012-08-09
JP5894202B2 (ja) 2016-03-23
MX2007005545A (es) 2007-07-05
ES2317319T3 (es) 2009-04-16
IL190497A0 (en) 2008-11-03
IL181446A (en) 2010-06-16
US20070248645A1 (en) 2007-10-25
MX2007003045A (es) 2007-08-02
CN101014317A (zh) 2007-08-08
IL190497A (en) 2012-01-31
ATE415942T1 (de) 2008-12-15
US20060100288A1 (en) 2006-05-11
ATE412400T1 (de) 2008-11-15
JP2012162549A (ja) 2012-08-30
ES2320574T3 (es) 2009-05-25
US20090028955A1 (en) 2009-01-29
US20080107738A1 (en) 2008-05-08
JP5773941B2 (ja) 2015-09-02
PT1809238E (pt) 2009-02-09
ATE412401T1 (de) 2008-11-15
CN103356481B (zh) 2017-11-28
DE602005011480D1 (de) 2009-01-15
DE602004017477D1 (de) 2008-12-11
ES2314354T3 (es) 2009-03-16
CN103356481A (zh) 2013-10-23
DE602005010733D1 (de) 2008-12-11
ES2319129T3 (es) 2009-05-04
CN101056615B (zh) 2011-05-11
JP2014088450A (ja) 2014-05-15
PT1809237E (pt) 2009-04-09
ATE418964T1 (de) 2009-01-15
ZA200703751B (en) 2008-08-27
US8273362B2 (en) 2012-09-25
US8372434B2 (en) 2013-02-12
US8298568B2 (en) 2012-10-30
DK1809237T3 (da) 2009-05-04
EP1655021A1 (de) 2006-05-10
IL181446A0 (en) 2007-07-04
US8298569B2 (en) 2012-10-30
CN101056615A (zh) 2007-10-17
NZ554929A (en) 2010-09-30
HK1107938A1 (en) 2008-04-25
DE602005026464D1 (de) 2011-03-31
IL182897A (en) 2010-12-30
IL182897A0 (en) 2007-08-19

Similar Documents

Publication Publication Date Title
ATE498392T1 (de) Ophthalmische emulsionen mit einem immunsuppressiven mittel
EP1929996A3 (de) Ophthalmische Emulsionen mit einem immunsuppressiven Mittel
Froelich et al. Microemulsion-based media in nose-to-brain drug delivery
BRPI0411306A (pt) composições farmacêuticas compreendendo compostos ativos de vitamina d
BRPI0506983A (pt) composições para terapia localizada dos olhos, compreendendo preferencialmente acetonida de triancinolona e ácido hialurÈnico
ES2134850T3 (es) Emulsiones farmaceuticas o cosmeticas aceite en agua de particulas cargadas positivamente.
WO2007137237A3 (en) Treatment of protein misfolding
BR0100424A (pt) Nanoemulsão óleo-em-água que contém lipìdios anfìfilos e um polìmero não iÈnico, composição cosmética de uso tópico, suas utilizações, processo de tratamento não terapêutico e processo para espessar as nanoemulsões óleo-em -água
DE69926862D1 (de) Kosmetische oder dermo-pharmazeutische zusammensetzung in form von hydrophoben perlen und herstellungsverfahren
WO2005072709A3 (en) Formulations for poorly soluble drugs
WO2005027822A3 (en) Stabilized formulations of phosphatidylserine
EP2293808A4 (de) Knochenformendes peptid 1 (bfp1) enthaltendes synthetisches peptid zur stimulierung der osteoblasten-differenzierung und das synthetische peptid enthaltende pharmazeutische zusammensetzung
DE60216305D1 (de) Zusammensetzungen zur verabreichung von arzneimittelkombinationen
DE602006006825D1 (de) Blockcopolymere, Verfahren zu deren Herstellung und ihre Verwendung in Emulsionen
DE60310605D1 (de) Nanoteilchen zur verabreichung von wirkstoffen, verfahren zur herstellung dieser teilchen und diese enthaltende zusammensetzung
Salamah et al. Development and characterization of in situ gelling nasal cilostazol spanlastics
DE60329968D1 (de) Dosierungsformen enthaltend Thyroidhormone und deren Herstellungsverfahren
FR2825272B1 (fr) Composition cosmetique comprenant des particules de silicate dans un support de type emulsion huile-dans-eau
EP1782824A3 (de) Pharmazeutische Zusammensetzungen, die Diaminooxidase enthalten
MA27850A1 (fr) Preparations pharmaceutiques contenant de l'amoxicilline et du clavulanate
DE602004015876D1 (de) Lichtschutzformulierung in der Form einer Öl-Wasser-Nanoemulsion, deren Herstellung und Verwendung in der Kosmetik und in der Dermatologie
DK1275383T3 (da) "Modified release" farmaceutisk komposition, der indeholder Bupropion HCI som aktivt stof
ATE521622T1 (de) ßNEUE PEPTIDE, DEREN DERIVATE, VERFAHREN ZU DEREN HERSTELLUNG, NEUE STÄMME, DIE DIESE SUBSTANZEN PRODUZIEREN, UND ANTIVIRALE MITTEL, DIE DIESE SUBSTANZEN ALS WIRKSTOFFE ENTHALTENß
TH45461C3 (th) องค์ประกอบของแชมพูสระผม

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties